The Food and Drug Administration rejected AcelRx Pharmaceuticals Inc.'s (Nasdaq: ACRX) needle-free pain medication device Zalviso sending the stock price plummeting $4.26 to $6.57.
FDA rejects AcelRx's Zalviso
July 28, 2014 at 15:42 PM EDT
FDA rejects AcelRx's ZalvisoJuly 28, 2014 at 15:42 PM EDT
The Food and Drug Administration rejected AcelRx Pharmaceuticals Inc.'s (Nasdaq: ACRX) needle-free pain medication device Zalviso sending the stock price plummeting $4.26 to $6.57. Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|